CRISPR Therapeutics (NASDAQ:CRSP) Receives “Neutral” Rating from Guggenheim

Guggenheim reissued their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research report published on Friday morning, Marketbeat.com reports.

Several other research analysts have also recently weighed in on CRSP. Oppenheimer lowered their target price on CRISPR Therapeutics from $102.00 to $95.00 and set an outperform rating on the stock in a report on Friday, May 10th. Piper Sandler reissued an overweight rating and set a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, June 17th. JMP Securities reaffirmed a market outperform rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Robert W. Baird boosted their price target on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a neutral rating in a research report on Thursday, May 9th. Finally, Wells Fargo & Company cut their price objective on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an equal weight rating for the company in a research report on Thursday, May 9th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of Hold and a consensus target price of $75.71.

Check Out Our Latest Stock Report on CRSP

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $54.01 on Friday. The business has a fifty day moving average price of $56.72 and a 200 day moving average price of $64.46. The company has a market cap of $4.59 billion, a P/E ratio of -19.86 and a beta of 1.78. CRISPR Therapeutics has a one-year low of $37.55 and a one-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. The company’s revenue was down 99.5% on a year-over-year basis. During the same period last year, the business earned ($0.67) EPS. As a group, sell-side analysts predict that CRISPR Therapeutics will post -5.51 EPS for the current fiscal year.

Insider Activity

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares in the company, valued at approximately $378,327.05. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Julianne Bruno sold 3,366 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares in the company, valued at $378,327.05. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. lifted its position in CRISPR Therapeutics by 159.4% in the third quarter. PNC Financial Services Group Inc. now owns 6,808 shares of the company’s stock valued at $309,000 after acquiring an additional 4,183 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of CRISPR Therapeutics during the third quarter worth about $201,000. Invesco Ltd. boosted its position in shares of CRISPR Therapeutics by 1.5% in the 3rd quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock valued at $6,179,000 after purchasing an additional 2,061 shares during the period. Ancora Advisors LLC grew its stake in CRISPR Therapeutics by 111.1% during the 3rd quarter. Ancora Advisors LLC now owns 1,330 shares of the company’s stock worth $60,000 after buying an additional 700 shares during the last quarter. Finally, Corton Capital Inc. increased its position in CRISPR Therapeutics by 6.1% during the third quarter. Corton Capital Inc. now owns 5,409 shares of the company’s stock worth $246,000 after buying an additional 313 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics is a gene-editing company on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.